Edition:
India

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

36.53USD
20 Sep 2019
Change (% chg)

$0.51 (+1.42%)
Prev Close
$36.02
Open
$36.00
Day's High
$36.71
Day's Low
$35.58
Volume
518,940
Avg. Vol
187,396
52-wk High
$42.91
52-wk Low
$18.56

Latest Key Developments (Source: Significant Developments)

Deciphera Pharma Reports Positive Early-Stage Trial Data For Stomach Cancer Drug
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS REPORTS POSITIVE UPDATED PHASE 1 DATA FOR RIPRETINIB IN GASTROINTESTINAL STROMAL TUMORS.DECIPHERA PHARMACEUTICALS INC - DATA FROM PHASE 1 STUDY SUPPORTS ONGOING INTRIGUE PHASE 3 CLINICAL STUDY IN PATIENTS WITH SECOND-LINE GIST.DECIPHERA PHARMACEUTICALS INC - ADDITIONAL PHASE 1 RESULTS EXPECTED TO BE PRESENTED AT UPCOMING MEDICAL MEETING.DECIPHERA PHARMACEUTICALS INC - MEDIAN PROGRESSION FREE SURVIVAL (MPFS) SUSTAINED ACROSS ALL COHORTS.  Full Article

Deciphera Pharma Announces Positive From Late-Stage Stomach Cancer Study
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM INVICTUS PIVOTAL PHASE 3 CLINICAL STUDY OF RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS.DECIPHERA PHARMACEUTICALS INC - INVICTUS ACHIEVED PRIMARY ENDPOINT.DECIPHERA PHARMACEUTICALS INC - MEDIAN PFS FOR RIPRETINIB OF 6.3 MONTHS VERSUS PLACEBO OF 1.0 MONTH; HAZARD RATIO OF 0.15, P<0.0001.DECIPHERA PHARMACEUTICALS INC - COMPANY EXPECTS TO SUBMIT AN NDA TO FDA IN 1Q 2020 FOR TREATMENT OF PATIENTS WITH ADVANCED GIST.DECIPHERA PHARMACEUTICALS INC - ANNOUNCED POSITIVE TOP-LINE DATA FROM INVICTUS PIVOTAL PHASE 3 CLINICAL STUDY OF RIPRETINIB.DECIPHERA PHARMACEUTICALS - INVICTUS STUDY ACHIEVED PRIMARY ENDPOINT OF IMPROVED PFS AS DETERMINED BY BLINDED INDEPENDENT CENTRAL RADIOLOGIC REVIEW.DECIPHERA PHARMACEUTICALS INC - RIPRETINIB WAS GENERALLY WELL TOLERATED.  Full Article

Deciphera Pharma And Zai Lab Ltd Announce Exclusive License Agreement For Ripretinib In Greater China
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. AND ZAI LAB LIMITED ANNOUNCE AN EXCLUSIVE LICENSE AGREEMENT FOR RIPRETINIB IN GREATER CHINA.DECIPHERA PHARMACEUTICALS INC - ZAI LAB TO LEAD DEVELOPMENT AND COMMERCIALIZATION OF RIPRETINIB IN GREATER CHINA.DECIPHERA PHARMACEUTICALS INC - TO RECEIVE $20 MILLION UPFRONT CASH PAYMENT, UP TO $185 MILLION IN POTENTIAL FUTURE MILESTONES AND ROYALTIES.DECIPHERA PHARMACEUTICALS INC - INTENDS TO EXPAND RIPRETINIB DEVELOPMENT PROGRAM IN GASTROINTESTINAL STROMAL TUMORS.DECIPHERA PHARMACEUTICALS INC - WILL BE ELIGIBLE TO RECEIVE UP TO $185 MILLION IN POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Deciphera Pharma Reports Q1 Loss Per Share Of $1.25
Friday, 10 May 2019 

May 9 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $1.25.Q1 EARNINGS PER SHARE ESTIMATE $-0.84 -- REFINITIV IBES DATA.ENDED Q1 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $262 MILLION.  Full Article

Deciphera Pharmaceuticals Initiates Phase 3 Study Of Ripretinib (Dcc-2618)
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS INITIATES PIVOTAL PHASE 3 CLINICAL STUDY OF RIPRETINIB (DCC-2618) IN SECOND-LINE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (“INTRIGUE” STUDY).DECIPHERA - EXPECT TO REPORT TOP-LINE DATA FROM FIRST PHASE 3 CLINICAL STUDY, INVICTUS, IN FOURTH-LINE AND FOURTH-LINE-PLUS GIST PATIENTS IN MID-2019.  Full Article

Deciphera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
Tuesday, 12 Jun 2018 

Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Deciphera Pharmaceuticals Q4 Loss Per Share $0.62
Thursday, 29 Mar 2018 

March 28 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.62.Q4 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.  Full Article

Deciphera Pharmaceuticals Q3 loss $5.85 per share​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Deciphera Pharmaceuticals Inc : :Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights.Qtrly loss $5.85 per share​.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article

New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing‍​.  Full Article

Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC ‍​as of Oct 2 - SEC filing‍​.  Full Article

Deciphera shares skyrocket as cancer drug improves progression-free survival

Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.